Documents
Resources
Learning Center
Upload
Plans & pricing Sign in
Sign Out

Seattle Genetics, Inc. (SGEN) - Financial and Strategic SWOT Analysis Review

VIEWS: 5 PAGES: 49

Seattle Genetics, Inc. (Seattle Genetics) is a biotechnology company. It develops and markets monoclonal antibody-based therapies for the treatment of cancer. The company's commercial product Adcetris (brentuximab vedotin) is an antibody-drug conjugate indicated to treat Hodgkin lymphoma (HL) and systemic anaplastic large cell lymphoma (sALCL). Seattle Genetics' product pipeline consists of four clinical-stage programs, that include SGN-75, ASG-5ME, ASG-22ME and SGN-CD19A; and several preclinical product candidates, such as, SGN-CD33A and SGN-LIV1A. It uses antibody-drug conjugate technology for the development of its product portfolio.

More Info
									          Seattle Genetics, Inc. (SGEN) - Financial and Strategic SWOT Analysis
                                          Review
        Reference Code: GDPH4301FSA                                                                                           Publication Date: MAR 2013

          21823 30th Drive SE                                Phone              +1 425 5274000                  Revenue          210.8 (million USD)
          Bothell, WA                                        Fax                +1 425 5274001                  Net Profit       -53.78 (million USD)
          98021                                              Website            www.seagen.com                  Employees        538
                                                                                                                                 Pharmaceuticals           &
          United States                                      Exchange           SGEN [NASDAQ]                   Industry
                                                                                                                                 Healthcare

       Company Overview
       Seattle Genetics, Inc. (Seattle Genetics) is a biotechnology company. It develops and markets monoclonal antibody-based
       therapies for the treatment of cancer. The company's commercial product Adcetris (brentuximab vedotin) is an antibody-drug
       conjugate indicated to treat Hodgkin lymphoma (HL) and systemic anaplastic large cell lymphoma (sALCL). Seattle Genetics'
       product pipeline consists of four clinical-stage programs, that include SGN-75, ASG-5ME, ASG-22ME and SGN-CD19A; and
       several preclinical product candidates, such as, SGN-CD33A and SGN-LIV1A. It uses antibody-drug conjugate technology for the
       development of its product portfolio.
       Key Executives                                                                SWOT Analysis
                      Name                                 Title                      Seattle Genetics, Inc., SWOT Analysis
         Clay B. Siegall, Ph.D.              Chairman                                 Strengths                              Weaknesses
         Srinivas     Akkaraju,     M.D., Director
                                                                                      Licensing Partnerships                 Revenue Concentration
         Ph.D.
         Felix J. Baker, Ph.D.               Director                                 Focused Research and                   Dependence on Third Parties
                                                                                      Development Efforts
         Franklin M. Berger                  Director
         David W. Gryska                     Director
        Source: Annual Report, Company Website, Primary and Secondary
                                                                                      Opportunities                          Threats
        Research, GlobalData
                                                                                      Lead Product: ADCETRIS                 Intense Competition
       Share Data
                                                                                      Strong Product Pipeline                Stringent Government
         Seattle Genetics, Inc.
                                                                                                                             Regulations
        Share Price (USD) as on 22-Mar-                                36.22
        2013
                                                                                     Source: Annual Report, Company Website, Primary and Secondary Research,
        EPS (USD)                                                       -0.46        GlobalData
        Market Cap (million USD)                                       4,314
        Enterprise Value (million USD)                                 3,949
        Shares Outstanding (million)                                     119
       Source: Annual Report, Company Website, Primary and Secondary
       Research, GlobalData

       Financial Performance                                                         Recent Developments
                                                                                      Feb 12, 2013         Seattle Genetics Reports Revenue Of $63.9m
                                                                                                           In Q4 2012
                                                                                      Nov 07, 2012         Seattle Genetics Reports Revenue Of $49.8m
                                                                                                           In Q3 2012
                                                                                      Aug 08, 2012         Seattle Genetics Reports Revenue Of $48.8m
                                                                                                           In Q2 2012
                                                                                      May 08, 2012         Seattle Genetics Reports Revenue Of $48.2m
                                                                                                           In Q1 2012
                                                                                     Source: Annual Report, Company Website, Primary and Secondary Research,
                                                                                     GlobalData
       Source: Annual Report, Company Website, Primary and Secondary
       Research, GlobalData




Seattle Genetics, Inc. (SGEN) - Financial and Strategic SWOT                                                                    Reference Code: GDPH4301FSA
Analysis Review
Source : www.globalcompanyintelligence.com                                                                                                                     Page 1
© GlobalData. This report is a licensed product and is not to be copied, reproduced, shared or resold in any form
       Table of Contents
       Table of Contents ............................................................................................................................................................................... 2
          List of Tables .................................................................................................................................................................................. 4
          List of Figures ................................................................................................................................................................................. 4
       Section 1 - About the Company.......................................................................................................................................................... 5
       Seattle Genetics, Inc. - Key Facts ...................................................................................................................................................... 5
       Seattle Genetics, Inc. - Key Employees ............................................................................................................................................. 6
       Seattle Genetics, Inc. - Key Employee Biographies ........................................................................................................................... 7
       Seattle Genetics, Inc. - Major Products and Services ........................................................................................................................ 8
       Seattle Genetics, Inc. - Pharmaceutical Pipeline Products Data ........................................................................................................ 9
          Seattle Genetics, Inc., Pipeline Products by Therapy Area............................................................................................................. 9
          Seattle Genetics, Inc., Pipeline Products by Development Phase ................................................................................................ 10
       Seattle Genetics, Inc. - History ......................................................................................................................................................... 13
       Seattle Genetics, Inc. - Company Statement.................................................................................................................................... 17
       Seattle Genetics, Inc. - Locations And Subsidiaries ......................................................................................................................... 19
          Head Office ................................................................................................................................................................................... 19
          Other Locations & Subsidiaries ..................................................................................................................................................... 19
       Section 2 – Company Analysis ......................................................................................................................................................... 20
       Seattle Genetics, Inc. - Business Description ................................................................................................................................... 20
       Seattle Genetics, Inc. - Corporate Strategy ...................................................................................................................................... 22
       Seattle Genetics, Inc. - SWOT Analysis ........................................................................................................................................... 23
          SWOT Analysis - Overview........................................................................................................................................................... 23
          Seattle Genetics, Inc. - Strengths ................................................................................................................................................. 23
             Strength - Licensing Partnerships ............................................................................................................................................. 23
             Strength - Focused Research and Development Efforts ........................................................................................................... 23
             Strength - Proprietary Antibody-Drug Conjugate Technologies ................................................................................................. 23
          Seattle Genetics, Inc. - Weaknesses ............................................................................................................................................ 24
             Weakness - Revenue Concentration ......................................................................................................................................... 24
             Weakness - Dependence on Third Parties ................................................................................................................................ 24
          Seattle Genetics, Inc. - Opportunities ........................................................................................................................................... 24
             Opportunity - Lead Product: ADCETRIS ................................................................................................................................... 24
             Opportunity - Strong Product Pipeline ....................................................................................................................................... 24
             Opportunity - Market Potential: Oncology.................................................................................................................................. 25
          Seattle Genetics, Inc. - Threats .................................................................................................................................................... 25
             Threat - Intense Competition ..................................................................................................................................................... 25
             Threat - Stringent Government Regulations .............................................................................................................................. 25
             Threat - Uncertain R&D Outcomes ........................................................................................................................................... 25
       Seattle Genetics, Inc. - Key Competitors .......................................................................................................................................... 26
       Section 3 – Company Financial Ratios ............................................................................................................................................. 27
       Financial Ratios - Capital Market Ratios........................................................................................................................................... 27
       Financial Ratios - Annual Ratios ...................................................................................................................................................... 27
       Performance Chart ........................................................................................................................................................................... 29
       Financial Performance...................................................................................................................................................................... 29
       Financial Ratios - Interim Ratios....................................................................................................................................................... 30
       Financial Ratios - Ratio Charts ......................................................................................................................................................... 31
       Section 4 – Company’s Lifesciences Financial Deals and Alliances ................................................................................................ 32


Seattle Genetics, Inc. (SGEN) - Financial and Strategic SWOT                                                                                                     Reference Code: GDPH4301FSA
Analysis Review
Source : www.globalcompanyintelligence.com                                                                                                                                                                Page 2
© GlobalData. This report is a licensed product and is not to be copied, reproduced, shared or resold in any form
          Seattle Genetics, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2007 to YTD 2013 .......................................................... 32
          Seattle Genetics, Inc., Pharmaceuticals & Healthcare, Deals By Type, 2007 to YTD 2013 ......................................................... 33
       Seattle Genetics, Inc., Recent Deals Summary................................................................................................................................ 34
       Section 5 – Company’s Recent Developments ................................................................................................................................ 35
          Seattle Genetics, Inc., Recent Developments............................................................................................................................... 35
             Feb 12, 2013: Seattle Genetics Reports Revenue Of $63.9m In Q4 2012 ................................................................................ 35
             Nov 07, 2012: Seattle Genetics Reports Revenue Of $49.8m In Q3 2012................................................................................ 36
             Aug 08, 2012: Seattle Genetics Reports Revenue Of $48.8m In Q2 2012................................................................................ 38
             May 08, 2012: Seattle Genetics Reports Revenue Of $48.2m In Q1 2012 ............................................................................... 39
             Apr 03, 2012: Seattle Genetics Presents Research Related To Antibody-Drug Conjugates At AACR 2012 ............................ 41
             Mar 21, 2012: Seattle Genetics Appoints Nancy Simonian To Board ....................................................................................... 42
             Feb 23, 2012: Seattle Gene
								
To top